Business Description
OncoZenge AB
ISIN : SE0015504097
Share Class Description:
FRA:8LY: Ordinary SharesCompare
Compare
Traded in other countries / regions
ONCOZ.Sweden8LY.Germany IPO Date
2021-02-17Description
OncoZenge AB is a pharmaceutical company that is developing a new treatment for effective pain relief in patients suffering from oral pain caused by radiation therapy and chemotherapy for cancer. In phase 2 patient studies, the company's product candidate BupiZenge displayed pain relief compared with standard therapy. It focuses on implementing a phase development program as a basis for regulatory approvals and product launches.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.91 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -131.1 | |||||
| 3-Year EPS without NRI Growth Rate | -150 | |||||
| 3-Year Book Growth Rate | -26.6 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 32.66 | |||||
| 9-Day RSI | 32.26 | |||||
| 14-Day RSI | 34.47 | |||||
| 6-1 Month Momentum % | 192.63 | |||||
| 12-1 Month Momentum % | 177.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.67 | |||||
| Quick Ratio | 5.67 | |||||
| Cash Ratio | 4.86 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -17.2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -56.68 | |||||
| ROA % | -52.07 | |||||
| ROIC % | -121.15 | |||||
| ROCE % | -56.65 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 4 | |||||
| Price-to-Tangible-Book | 8.69 | |||||
| EV-to-EBIT | -3.17 | |||||
| EV-to-Forward-EBIT | -3.01 | |||||
| EV-to-EBITDA | -3.17 | |||||
| EV-to-Forward-EBITDA | -3.01 | |||||
| EV-to-Forward-Revenue | 0.41 | |||||
| EV-to-FCF | -2.77 | |||||
| Price-to-Net-Current-Asset-Value | 8.69 | |||||
| Price-to-Net-Cash | 11.58 | |||||
| Earnings Yield (Greenblatt) % | -31.55 | |||||
| FCF Yield % | -21.43 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
OncoZenge AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -0.071 | ||
| Beta | -0.53 | ||
| Volatility % | 88.91 | ||
| 14-Day RSI | 34.47 | ||
| 14-Day ATR (€) | 0.060444 | ||
| 20-Day SMA (€) | 0.609025 | ||
| 12-1 Month Momentum % | 177.08 | ||
| 52-Week Range (€) | 0.228 - 0.993 | ||
| Shares Outstanding (Mil) | 11.71 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
OncoZenge AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
OncoZenge AB Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
OncoZenge AB Frequently Asked Questions
What is OncoZenge AB(FRA:8LY)'s stock price today?
The current price of FRA:8LY is €0.35. The 52 week high of FRA:8LY is €0.99 and 52 week low is €0.23.
When is next earnings date of OncoZenge AB(FRA:8LY)?
The next earnings date of OncoZenge AB(FRA:8LY) is 2025-02-14 Est..
Does OncoZenge AB(FRA:8LY) pay dividends? If so, how much?
OncoZenge AB(FRA:8LY) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers